Eugeen Vanmechelen

23.0k total citations · 6 hit papers
162 papers, 14.3k citations indexed

About

Eugeen Vanmechelen is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Eugeen Vanmechelen has authored 162 papers receiving a total of 14.3k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Physiology, 79 papers in Psychiatry and Mental health and 48 papers in Molecular Biology. Recurrent topics in Eugeen Vanmechelen's work include Alzheimer's disease research and treatments (138 papers), Dementia and Cognitive Impairment Research (78 papers) and Parkinson's Disease Mechanisms and Treatments (16 papers). Eugeen Vanmechelen is often cited by papers focused on Alzheimer's disease research and treatments (138 papers), Dementia and Cognitive Impairment Research (78 papers) and Parkinson's Disease Mechanisms and Treatments (16 papers). Eugeen Vanmechelen collaborates with scholars based in Belgium, Sweden and United Kingdom. Eugeen Vanmechelen's co-authors include Kaj Blennow, Hugo Vanderstichele, Pia Davidsson, Niels Andreasen, Lennart Minthon, Henrik Zetterberg, Ross Jakes, Michel Goedert, Anders Wallin and Bengt Winblad and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Brain.

In The Last Decade

Eugeen Vanmechelen

158 papers receiving 14.0k citations

Hit Papers

tau protein in cerebrospinal fluid 1995 2026 2005 2015 1995 1999 1999 2021 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. tau protein in cerebrospinal fluid
    1995 636 citations Kaj Blennow, Anders Wallin et al. profile →
  2. Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
    1999 563 citations Frank Hulstaert, Kaj Blennow et al. profile →
  3. Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease
    1999 543 citations Niels Andreasen, Pia Davidsson et al. profile →
  4. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
    2021 390 citations Nicholas J. Ashton, Thomas K. Karikari et al. profile →
  5. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
    2022 242 citations Nicholas J. Ashton, Jeroen Vanbrabant et al. profile →
  6. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
    2021 146 citations Andreas Jeromin, Nicholas J. Ashton et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eugeen Vanmechelen Belgium 66 10.8k 6.5k 4.3k 2.8k 2.8k 162 14.3k
Hugo Vanderstichele Belgium 57 10.8k 1.0× 6.6k 1.0× 4.6k 1.1× 2.5k 0.9× 2.0k 0.7× 156 14.8k
Ulf Andréasson Sweden 57 7.7k 0.7× 4.9k 0.7× 3.9k 0.9× 2.5k 0.9× 3.4k 1.2× 178 13.7k
Teresa Gómez‐Isla United States 55 8.5k 0.8× 3.5k 0.5× 3.6k 0.8× 2.8k 1.0× 2.3k 0.8× 116 13.7k
Dietmar Rudolf Thal Germany 60 11.5k 1.1× 4.9k 0.8× 5.1k 1.2× 4.6k 1.6× 5.0k 1.8× 234 19.1k
Eileen H. Bigio United States 47 6.7k 0.6× 3.1k 0.5× 3.5k 0.8× 2.5k 0.9× 4.6k 1.6× 144 12.6k
Suzanne S. Mirra United States 45 10.3k 1.0× 5.3k 0.8× 4.4k 1.0× 3.2k 1.2× 4.4k 1.6× 101 16.4k
Michael C. Irizarry United States 56 8.4k 0.8× 3.0k 0.5× 3.4k 0.8× 2.2k 0.8× 1.9k 0.7× 166 13.2k
Daniel W. McKeel United States 45 9.9k 0.9× 6.1k 0.9× 4.4k 1.0× 2.9k 1.0× 2.1k 0.7× 82 16.5k
Nigel J. Cairns United States 58 8.5k 0.8× 4.1k 0.6× 5.4k 1.2× 3.4k 1.2× 6.8k 2.4× 181 17.6k
Eric Siemers United States 45 7.2k 0.7× 4.5k 0.7× 2.6k 0.6× 1.7k 0.6× 1.7k 0.6× 167 12.0k

Countries citing papers authored by Eugeen Vanmechelen

Since Specialization
Citations

This map shows the geographic impact of Eugeen Vanmechelen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugeen Vanmechelen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugeen Vanmechelen more than expected).

Fields of papers citing papers by Eugeen Vanmechelen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugeen Vanmechelen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugeen Vanmechelen. The network helps show where Eugeen Vanmechelen may publish in the future.

Co-authorship network of co-authors of Eugeen Vanmechelen

This figure shows the co-authorship network connecting the top 25 collaborators of Eugeen Vanmechelen. A scholar is included among the top collaborators of Eugeen Vanmechelen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugeen Vanmechelen. Eugeen Vanmechelen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goossens, Julie, Isabel Sala, María Belén Sánchez‐Saudinós, et al.. (2025). Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer’s pathophysiological biomarkers. Alzheimer s Research & Therapy. 17(1). 51–51. 2 indexed citations
2.
Cline, Erika N., Karen Sundell, Elizabeth A. Johnson, et al.. (2025). Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(4). 100082–100082. 2 indexed citations
3.
Sauer, Mathias, Julie Goossens, Andréa Lessa Benedet, et al.. (2023). Blood‐based SNAP‐25 and VAMP‐2 in Alzheimer’s disease; relation to cognition, atrophy and synaptic density.. Alzheimer s & Dementia. 19(S24). 4 indexed citations
4.
Molfetta, Guglielmo Di, Andreas Jeromin, Eugeen Vanmechelen, et al.. (2023). The detection of phosphorylated tau in tear fluid. Alzheimer s & Dementia. 19(S24). 1 indexed citations
5.
Goossens, Julie, Juan Fortea, Daniel Alcolea, et al.. (2023). Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum. Alzheimer s Research & Therapy. 15(1). 186–186. 11 indexed citations
6.
Lantero‐Rodriguez, Juan, Agathe Vrillon, Aida Fernández‐Lebrero, et al.. (2023). Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Alzheimer s Research & Therapy. 15(1). 48–48. 6 indexed citations
7.
Kumar, Pankaj, Jeroen Vanbrabant, Mary Joy Encarnacion, et al.. (2022). The effects of age and sex on plasma p‐tau181 concentrations in Alzheimer’s Disease. Alzheimer s & Dementia. 18(S5). 1 indexed citations
8.
Jacobs, Dirk, Giovanni Bellomo, Federico Paolini Paoletti, et al.. (2022). A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. Journal of Alzheimer s Disease. 90(1). 363–380. 22 indexed citations
9.
Willemse, Eline A.J., et al.. (2022). Bioinformatics tools and data resources for assay development of fluid protein biomarkers. Biomarker Research. 10(1). 83–83. 10 indexed citations
10.
Doorn, Linda Josephine Christine van Waalwijk van, Marleen J.A. Koel‐Simmelink, Ute Haußmann, et al.. (2016). Validation of soluble amyloid‐β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. Journal of Neurochemistry. 137(1). 112–121. 17 indexed citations
11.
Violet, Marie, Dirk Jacobs, Pierre Grognet, et al.. (2014). Tau Monoclonal Antibody Generation Based on Humanized Yeast Models. Journal of Biological Chemistry. 290(7). 4059–4074. 19 indexed citations
12.
Öhrfelt, Annika, Henrik Zetterberg, Kerstin Andersson, et al.. (2011). Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochemical Research. 36(11). 2029–2042. 89 indexed citations
13.
Bastard, Nathalie Le, J.J. Martin, Eugeen Vanmechelen, et al.. (2009). Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurodegenerative Diseases. 6(1). 1896. 3 indexed citations
14.
Vanderstichele, Hugo, K De Vreese, Kaj Blennow, et al.. (2006). Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine (CCLM). 44(12). 1472–80. 131 indexed citations
15.
Höglund, Kina, Karin Thelen, Magnus Sjögren, et al.. (2005). The Effect of Simvastatin Treatment on the Amyloid Precursor Protein and Brain Cholesterol Metabolism in Patients with Alzheimer’s Disease. Dementia and Geriatric Cognitive Disorders. 19(5-6). 256–265. 77 indexed citations
16.
Skoog, Ingmar, Pia Davidsson, Ólafur Aevarsson, et al.. (2003). Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds. Dementia and Geriatric Cognitive Disorders. 15(3). 169–176. 151 indexed citations
17.
Sjögren, Magnus, Lennart Minthon, Pia Davidsson, et al.. (2000). CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. Journal of Neural Transmission. 107(5). 563–579. 205 indexed citations
18.
Kerschaver, E Van, Penelope Brock, Hans Pottel, et al.. (2000). Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia. 14(12). 2076–2084. 20 indexed citations
19.
Cruts, Marc, C. De Jonghe, Carolyn Tysoe, et al.. (1999). Aberrant splicing in the presenilin-1 intron 4 mutation causes presenile Alzheimers disease by increased a beta 42 secretion. The American Journal of Human Genetics. 65(4). 10 indexed citations
20.
Blennow, Kaj & Eugeen Vanmechelen. (1998). Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing. Journal of neural transmission. Supplementum. 53. 223–235. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hugo Vanderstichele Breakdown of academic impact, for papers by Ulf Andréasson Breakdown of academic impact, for papers by Teresa Gómez‐Isla Breakdown of academic impact, for papers by Dietmar Rudolf Thal Breakdown of academic impact, for papers by Eileen H. Bigio Breakdown of academic impact, for papers by Suzanne S. Mirra Breakdown of academic impact, for papers by Michael C. Irizarry Breakdown of academic impact, for papers by Daniel W. McKeel Breakdown of academic impact, for papers by Nigel J. Cairns Breakdown of academic impact, for papers by Eric Siemers
Rankless by CCL
2026